メインコンテンツに移動

Specialist managers see more shorting activity

Accounting anomalies and heavy debt mean shorting is on a roll

James Fiore, primary manager of the Life Science Group Partners sector hedge fund, says the biotech and pharmaceutical-focused fund is presently 'predominantly in biotechnology' as the industry has had 'its worst bear market ever and is over 45% down for the year.'

Fiore says: 'Biotech is dominated in the US by individual investors and they're very skittish at the moment, so finding value in the

コンテンツを印刷またはコピーできるのは、有料の購読契約を結んでいるユーザー、または法人購読契約の一員であるユーザーのみです。

これらのオプションやその他の購読特典を利用するには、info@risk.net にお問い合わせいただくか、こちらの購読オプションをご覧ください: http://subscriptions.risk.net/subscribe

現在、このコンテンツをコピーすることはできません。詳しくはinfo@risk.netまでお問い合わせください。

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

無料メンバーシップの内容をお知りになりたいですか?ここをクリック

パスワードを表示
パスワードを非表示にする

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

ログイン
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here